製品名:4-(Chloromethyl)benzyl Alcohol

IUPAC Name:[4-(chloromethyl)phenyl]methanol

CAS番号:16473-35-1
分子式:C8H9ClO
純度:97%
カタログ番号:CM116221
分子量:156.61

包装単位 有効在庫 価格(USD) 数量
CM116221-1000g in stock ƴƐȯȯ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:16473-35-1
分子式:C8H9ClO
融点:-
SMILESコード:ClCC1=CC=C(C=C1)CO
密度:
カタログ番号:CM116221
分子量:156.61
沸点:275.9°C at 760 mmHg
MDL番号:MFCD03427011
保管方法:Store at 2-8°C.

Category Infos

Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Alcohols
Alcohol is a type of organic compound that carries at least one hydroxyl ( −OH) functional group bound to a saturated carbon atom.
Sebetralstat
KalVista Pharmaceuticals recently announces Phase 3 KONFIDENT trial of Sebetralstat meets all primary and key secondary endpoints as first oral on-demand therapy for Hereditary Angioedema (HAE). HAE is a rare and potentially life-threatening genetic disease caused by low levels or dysfunction of the C1 inhibitor, associated with uncontrolled plasma kallikrein (PKa) activity and generation of bradykinin (BK).
Sebetralstat is an investigational novel, oral plasma kallikrein inhibitor with a favorable safety profile. It works by targeting the kallikrein–kinin system (KKS), reducing the activity of plasma kallikrein and blocking uncontrolled bradykinin release in HAE attack. The Phase 3 results also show rapid symptom relief in a broad HAE population.